Read this company snapshot
Daily valuation snapshot
Bicycle Therapeutics plc American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $3.89
- Market capitalization (USD)
- $271,577,024.05
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.53
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BCYC in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BCYC in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing BCYC with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $3.89 |
| Market capitalization (USD) | $271,577,024.05 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.53 |
No matching rows. Clear the filter to see all records.
Read BCYC's valuation metrics
Company size
Bicycle Therapeutics plc American Depositary Shares's recorded market capitalization is $271,577,024.05. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
BCYC's recorded price-to-book ratio is 0.53. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Bicycle Therapeutics plc American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about BCYC. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow BCYC's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.